HUTCHMED (China) Ltd
HCM Nasdaq· Pharmaceutical Preparations
Last close · Oct 30, 2026
$13.15
KIRA · Stoqly’s AI analyst, in plain words
- HUTCHMED (China) Ltd had $549M of revenue in fiscal 2025, down 13.0% on the year before. Over five years, revenue changed +19.2% a year on average.
- Its operating margin was −7.1%, down 0.2 pts: of every 100 in sales, about −7 is left after running the business.
- HUTCHMED (China) Ltd made $457M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 11.2% a year.
- Free cash flow was −$78.8M in fiscal 2025, −14.4% of revenue. At that burn of $78.8M a year, its $1.4B of cash and short-term investments would last about 17.4 years.
- HUTCHMED (China) Ltd has $1.2B more cash than debt.
Market cap
$2.3B
P/E
5.1x
Revenue
$549M
Net income
$457M
Free cash flow
−$78.8M
Operating margin
−7.1%
HUTCHMED (China) Ltd in 30 seconds · fiscal 2025
Are sales growing?
−13.0%
No. Sales fell 13.0% last year.
Does it make a profit?
83.3%
Yes. It keeps 83.3% of every sale as profit.
How long would its cash last?
17.4 yrs
Comfortably. It burns $78.8M a year and holds $1.4B, about 17.4 years at that pace.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
5.1x
One share costs 5.1 times its yearly profit per share.
What HUTCHMED (China) Ltd does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 5, 2026
- Legal name
- HUTCHMED (China) Ltd
- CIK
- 0001648257
HUTCHMED (China) Ltd · HCM · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $356M | $426M | $838M | $630M | $549M |
| Revenue growth | 56.2% | 19.7% | 96.5% | −24.8% | −13.0% |
| Gross margin | — | 27.0% | 54.1% | 44.6% | 38.7% |
| Operating margin | −92.2% | −95.6% | 2.2% | −6.9% | −7.1% |
| Net income | −$195M | −$361M | $101M | $37.7M | $457M |
| Net margin | −54.7% | −84.6% | 12.0% | 6.0% | 83.3% |
| Diluted EPS | −$1.25 | −$2.15 | $0.60 | $0.20 | $2.60 |
| Cash | |||||
| Cash from operations | −$204M | −$269M | $219M | $0.5M | −$64.7M |
| Capital expenditure | $16.4M | $36.7M | $32.6M | $17.9M | $14.1M |
| Free cash flow | −$221M | −$305M | $187M | −$17.4M | −$78.8M |
| FCF margin | −62.0% | −71.6% | 22.3% | −2.8% | −14.4% |
| Share buybacks | $27.3M | $48.1M | $9.1M | $36.1M | — |
| Share count change | 13.6% | 6.9% | 2.6% | 0.4% | 0.0% |
| Debt and strength | |||||
| Cash and short-term investments | $1.0B | $631M | $886M | $836M | $1.4B |
| Debt incl. finance leases | $26.9M | $18.1M | $110M | $106M | $118M |
| Deposits | $2.1M | $3.6M | $1.6M | $1.6M | $1.7M |
| Shareholders' equity | $987M | $610M | $731M | $760M | $1.2B |
| Net debt / EBITDA | — | — | −29.2x | — | — |
| Current ratio | 3.9x | 2.4x | 2.7x | 2.8x | 5.0x |
| Interest coverage | −554.6x | −625.3x | 24.2x | −15.2x | −13.7x |
| Returns and quality | |||||
| Return on capital | −12,362.7% | — | — | −115.1% | — |
| Return on equity | −26.5% | −45.2% | 15.0% | 5.1% | 45.7% |
| Return on tangible equity | −19.8% | −59.4% | 13.9% | 5.0% | 37.3% |
| Piotroski F-score | 3 | 3 | 7 | 4 | 4 |
| Altman Z'' | 4.4 | −1.0 | 2.9 | 2.8 | 6.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
HUTCHMED (China) Ltd · HCM · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $13.15 a share, the company is worth $2.3B: 5.1 times its earnings of the last four quarters.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001648257). Latest version: stoqly.net/companies/hcm. Data updated November 1, 2026. For information only — not investment advice. Check the original filings before relying on any figure.